{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GIP+infusion",
    "query": {
      "intervention": "GIP infusion"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 11,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GIP+infusion&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T15:12:06.078Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01951716",
      "title": "Effects of Xenin-25 on Insulin Secretion and Gastric Emptying in Humans With and Without a Complete Truncal Vagotomy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Does the Vagus Nerve Mediate the Effects of Xenin-25"
      ],
      "interventions": [
        {
          "name": "Graded Glucose Infusion with Placebo",
          "type": "DRUG"
        },
        {
          "name": "Graded Glucose Infusion with GIP Alone",
          "type": "DRUG"
        },
        {
          "name": "Graded Glucose Infusion with xenin-25 alone",
          "type": "DRUG"
        },
        {
          "name": "Graded Glucose Infusion with GIP plus xenin-25",
          "type": "DRUG"
        },
        {
          "name": "Meal Tolerance Test with Placebo",
          "type": "DRUG"
        },
        {
          "name": "Meal Tolerance Test with xenin-25",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 0,
      "start_date": "2013-01",
      "completion_date": "2018-07",
      "has_results": false,
      "last_update_posted_date": "2018-04-26",
      "last_synced_at": "2026-09-02T15:12:06.078Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01951716"
    },
    {
      "nct_id": "NCT01951729",
      "title": "The Role of Cholinergic Signaling for Mediating the Effects of GIP and/or Xenin-25 on Insulin Secretion",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pre-diabetes"
      ],
      "interventions": [
        {
          "name": "Control",
          "type": "DRUG"
        },
        {
          "name": "Xenin-25 without atropine",
          "type": "DRUG"
        },
        {
          "name": "GIP without atropine",
          "type": "DRUG"
        },
        {
          "name": "Placebo with atropine",
          "type": "DRUG"
        },
        {
          "name": "Xenin-25 with atropine",
          "type": "DRUG"
        },
        {
          "name": "GIP with atropine",
          "type": "DRUG"
        },
        {
          "name": "GIP plus Xenin-25 without atropine",
          "type": "DRUG"
        },
        {
          "name": "GIP plus Xenin-25 with atropine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 15,
      "start_date": "2013-03-13",
      "completion_date": "2015-05",
      "has_results": false,
      "last_update_posted_date": "2018-05-25",
      "last_synced_at": "2026-09-02T15:12:06.078Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01951729"
    },
    {
      "nct_id": "NCT02550548",
      "title": "Incretin Action in Physiology and Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Insulin Secretion"
      ],
      "interventions": [
        {
          "name": "GIP infusion",
          "type": "DRUG"
        },
        {
          "name": "GLP-1 infusion",
          "type": "DRUG"
        },
        {
          "name": "Ex-9 infusion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "David D'Alessio, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 39,
      "start_date": "2016-04-21",
      "completion_date": "2021-04-16",
      "has_results": false,
      "last_update_posted_date": "2023-11-18",
      "last_synced_at": "2026-09-02T15:12:06.078Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02550548"
    },
    {
      "nct_id": "NCT00239707",
      "title": "GIP: Glucose-dependent Insulinotropic Peptide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "GIP",
          "type": "DRUG"
        },
        {
          "name": "Modified GIP",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute on Aging (NIA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2003-02",
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2013-11-28",
      "last_synced_at": "2026-09-02T15:12:06.078Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00239707"
    },
    {
      "nct_id": "NCT01694004",
      "title": "Nutrient Sensing in the Duodenum",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "The Effect of LCFA on Nutrient Absorption"
      ],
      "interventions": [
        {
          "name": "Benzocaine Infusion into Duodenum",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 16,
      "start_date": "2012-11",
      "completion_date": "2014-10-27",
      "has_results": false,
      "last_update_posted_date": "2024-04-11",
      "last_synced_at": "2026-09-02T15:12:06.078Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01694004"
    },
    {
      "nct_id": "NCT02398383",
      "title": "Role of Glucagon In Glucose Control in Cystic Fibrosis Related Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Cystic Fibrosis",
        "Cystic Fibrosis Related Diabetes"
      ],
      "interventions": [
        {
          "name": "Oral Glucose Tolerance Test",
          "type": "OTHER"
        },
        {
          "name": "Mixed Meal Tolerance Test",
          "type": "OTHER"
        },
        {
          "name": "Hypoglycemic Clamp",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "12 Years to 45 Years"
      },
      "enrollment_count": 7,
      "start_date": "2015-03",
      "completion_date": "2017-06-22",
      "has_results": false,
      "last_update_posted_date": "2020-06-26",
      "last_synced_at": "2026-09-02T15:12:06.078Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02398383"
    },
    {
      "nct_id": "NCT01851694",
      "title": "Beta-cell Response to Incretin Hormones in Cystic Fibrosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cystic Fibrosis",
        "Pancreatic Insufficiency"
      ],
      "interventions": [
        {
          "name": "GLP-1",
          "type": "DRUG"
        },
        {
          "name": "GIP",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2013-05",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-01-14",
      "last_synced_at": "2026-09-02T15:12:06.078Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01851694"
    },
    {
      "nct_id": "NCT06445075",
      "title": "Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Overweight and Obesity"
      ],
      "interventions": [
        {
          "name": "Apitegromab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Scholar Rock, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 102,
      "start_date": "2024-05-21",
      "completion_date": "2025-06-17",
      "has_results": false,
      "last_update_posted_date": "2026-01-23",
      "last_synced_at": "2026-09-02T15:12:06.078Z",
      "location_count": 7,
      "location_summary": "Chula Vista, California • Orlando, Florida • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Marrero",
          "state": "Louisiana"
        },
        {
          "city": "Norman",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06445075"
    },
    {
      "nct_id": "NCT00949663",
      "title": "Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Glucose-dependent Insulinotropic Polypeptide (GIP)",
          "type": "DRUG"
        },
        {
          "name": "Xenin-25",
          "type": "DRUG"
        },
        {
          "name": "Glucose-dependent Insulinotropic Polypeptide plus Xenin-25",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 38,
      "start_date": "2009-10",
      "completion_date": "2014-02",
      "has_results": false,
      "last_update_posted_date": "2014-07-22",
      "last_synced_at": "2026-09-02T15:12:06.078Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00949663"
    },
    {
      "nct_id": "NCT05375968",
      "title": "Splanchnic Venous Capacitance in Postural Tachycardia Syndrome",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Postural Tachycardia Syndrome (POTS)"
      ],
      "interventions": [
        {
          "name": "Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls POTS patients",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Compare change is SVC and SMA flow due to GIP antagonist GIP(3-30)NH2",
          "type": "DRUG"
        },
        {
          "name": "Compare change is SVC and SMA flow due to saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 50,
      "start_date": "2023-02-25",
      "completion_date": "2028-06-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-05",
      "last_synced_at": "2026-09-02T15:12:06.078Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05375968"
    }
  ]
}